Infiltration of CD4, CD8, CD56, and Fox-P3-positive lymphocytes in breast carcinoma tissue after neoadjuvant chemotherapy with or without trastuzumab1
Breast Disease · 26.06.2019 · 38 (2) · 57-65
DOI: 10.3233/bd-180350 ↗Kurz gefasst
Fachartikel in der Zeitschrift Breast Disease, erschienen am 26.06.2019. Verfasst von Naoko Itoi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga, 520-2192, Japan. Hauptthemen laut MEDLINE: Adaptive Immunity, Immunity, Cellular, Neoadjuvant Therapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
BACKGROUND: Trastuzumab (Tz) is assumed to prime antibody-dependent cellular cytotoxicity (ADCC); however, it remains unclear whether Tz therapy can clinically induce adaptive cellular immunity. OBJECTIVE: Adaptive Cellular Immune Effect of Tz Therapy. METHODS: This study included 29 surgical invasive breast carcinomas administered neoadjuvant chemotherapy with Tz (15 cases) or without Tz (14 cases). The numbers of immunoreactive cells (CD4, CD8, CD56, and Fox-P3) in three different compartments (intratumoral, adjacent stromal, and distant stromal) were determined. RESULTS: The average number of adjacent stromal CD4-positive, CD8-positive, and Fox-P3-positive cells in the Tz+ group was significantly greater than that in the Tz− group (p = 0.036, 0.0049, and 0.043, respectively). However, the number of Fox-P3-positive cells was much less than that of CD4-positive cells. Moreover, distant stromal CD4-positive and CD8-positive cells in the Tz+ group was also significantly greater than that of the Tz− group (p = 0.029 and 0.032, respectively). Only a small number of CD56-positive natural killer cells, playing a main role in ADCC, accumulated at the tumor site after Tz therapy. CONCLUSIONS: The results suggest that Tz therapy induces adaptive cellular immunity, including infiltration of both CD4-positive helper T cells and CD8-positive cytotoxic T cells into the breast carcinoma lesion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Surgery, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga, 520-2192, Japan.
- Consortium for Community Medicine, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga, 520-2192, Japan.
- Department of Breast surgery, Japan Community Healthcare Organization (JCHO) Shiga Hospital, 16-1 Fujimidai, Shiga, 520-0846, Japan.
- Department of Pathology and Laboratory Medicine, Kansai Medical University, 2-3-1, Shin-machi, Hirakata, Osaka, 573-1191, Japan.
- Department of Clinical Laboratory Medicine and Division of Diagnostic Pathology, Shiga University of Medical Science, Tsukinowa-cho, Seta, Otsu, Shiga, 520-2192, Japan.
Zitieren
APA
Itoi, N., Umeda, T., Ishida, M., Murata, S., Mori, T., Kawai, Y., Tomida, K., Shimizu, T., Kushima, R., & Tani, M. (2019). Infiltration of CD4, CD8, CD56, and Fox-P3-positive lymphocytes in breast carcinoma tissue after neoadjuvant chemotherapy with or without trastuzumab1. Breast Disease, 38(2), 57-65. https://doi.org/10.3233/bd-180350
Vancouver
Itoi N, Umeda T, Ishida M, Murata S, Mori T, Kawai Y, et al. Infiltration of CD4, CD8, CD56, and Fox-P3-positive lymphocytes in breast carcinoma tissue after neoadjuvant chemotherapy with or without trastuzumab1. Breast Disease. 2019;38(2):57-65. doi:10.3233/bd-180350
BibTeX
@article{Itoi2019,
author = {Itoi, Naoko and Umeda, Tomoko and Ishida, Mitsuaki and Murata, Satoshi and Mori, Tsuyoshi and Kawai, Yuki and Tomida, Kaori and Shimizu, Tomoharu and Kushima, Ryoji and Tani, Masaji},
title = {Infiltration of CD4, CD8, CD56, and Fox-P3-positive lymphocytes in breast carcinoma tissue after neoadjuvant chemotherapy with or without trastuzumab1},
journal = {Breast Disease},
year = {2019},
volume = {38},
number = {2},
pages = {57--65},
doi = {10.3233/bd-180350}
}
EUVIMED